絞り込み

16643

広告

Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.

著者 Wilson H , Dervenoulas G , Pagano G , Koros C , Yousaf T , Picillo M , Polychronis S , Simitsi A , Giordano B , Chappell Z , Corcoran B , Stamelou M , Gunn RN , Pellecchia MT , Rabiner EA , Barone P , Stefanis L , Politis M
Lancet Neurol.2019 Jun 19 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (4view , 0users)

Full Text Sources

Miscellaneous

Because of the highly penetrant gene mutation and clinical features consistent with idiopathic Parkinson's disease, carriers of the autosomal dominant Ala53Thr (A53T; 209G→A) point mutation in the α-synuclein (SNCA) gene are an ideal population to study the premotor phase and evolution of Parkinson's pathology. Given the known neurochemical changes in the serotonergic system and their association with symptoms of Parkinson's disease, we hypothesised that carriers of the A53T SNCA mutation might show abnormalities in the serotonergic neurotransmitter system before the diagnosis of Parkinson's disease, and that this pathology might be associated with measures of Parkinson's burden.
PMID: 31229470 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード